United Therapeutics

United Therapeutics announces presentations on Tyvaso DPI® at CHEST 2024, including long-term outcomes from the BREEZE study, and sponsors symposium on clinical pearls and drug-device characteristics.

Summit Therapeutics, a 21-year-old biotech with 130 employees and no revenue, saw its market cap surge due to positive data on its cancer drug candidate, ivonescimab, outperforming Merck's Keytruda. Co-CEO Maky Zanganeh's shares rose 17-fold, making her a billionaire. The drug, licensed from Akeso, requires a global Phase 3 trial for FDA approval. Zanganeh, born in Iran, followed an unconventional path to biotech leadership, collaborating with co-CEO Robert Duggan, who turned around Pharmacyclics.

AbbVie, a pharmaceutical firm with strong immunology and oncology portfolios, is compared against key competitors in the Biotechnology industry. The analysis reveals AbbVie's high Price to Earnings (64.53), Price to Book (50.28), and Price to Sales (6.22) ratios, suggesting a potentially overvalued stock. However, its high Return on Equity (18.4%), EBITDA ($5.0B), and gross profit ($10.26B) indicate strong profitability and operational efficiency. The company's low revenue growth (4.31%) compared to the industry average (28.79%) raises concerns about future performance.

United Therapeutics found liable for breaching 2015 agreement with Sandoz, resolving patent dispute; court ruled in favor of Sandoz Inc.

Court finds United Therapeutics' interference with generic Treprostinil Injection launch caused over $137 million in losses; proceeds from litigation to be split equally between Sandoz and Liquidia PAH, with Liquidia PAH's share further divided between Henderson SPV and PBM RG Holdings.

Liquidia Corporation announced that the US District Court found United Therapeutics' interference with the launch of generic Treprostinil Injection caused over $137M in losses. The decision stems from a 2019 lawsuit alleging antitrust violations and breach of contract, with the final damage award yet to be determined.

Regeneron Pharmaceuticals' PE, PB, and PS ratios are low, suggesting potential undervaluation. However, its low ROE indicates lower profitability. High EBITDA and gross profit levels indicate strong financial performance, but low revenue growth may be a concern.

Roivant's Pulmovant launches with a plan to develop Bayer's mosliciguat for PH-ILD, with a deal worth up to $294 million. Phase 1b trial results showed sustained reduction in PVR, suggesting potential differentiation in efficacy, safety, and convenience. Pulmovant aims to start a phase 2 trial in 2026.